BRISTOL MYERS SQUIBB
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 137
- Registration Number
- NCT00355238
- Locations
- 🇺🇸
Univ Of Texas Southwestern, Dallas, Texas, United States
🇺🇸Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 44
- Registration Number
- NCT00352560
- Locations
- 🇪🇸
Local Institution, Madrid, Spain
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2009-09-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT00351325
- Locations
- 🇺🇸
University Of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸Magee-Womens Hospital Of Upmc, Pittsburgh, Pennsylvania, United States
🇺🇸University Of Virginia, Charlottesville, Virginia, United States
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00349518
- Locations
- 🇬🇧
Local Institution, Birmingham, West Midlands, United Kingdom
🇵🇱Local Instiution, Lodz, Poland
A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 194
- Registration Number
- NCT00345748
- Locations
- 🇯🇵
Local Institution, Tochigi, Japan
Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2009-11-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 53
- Registration Number
- NCT00344552
- Locations
- 🇯🇵
Local Institution, Saitama, Japan
Study to Evaluate The Analgesic Efficacy and Safety of Intravenous Paracetamol in Subjects With Postoperative Pain After Total Hip Arthroplasty
- First Posted Date
- 2006-06-26
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 86
- Registration Number
- NCT00344045
- Locations
- 🇪🇸
Local Institution, Vizcaya, Spain
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2010-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT00339144
- Locations
- 🇯🇵
Local Institution, Koto-Ku, Tokyo, Japan
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 48
- Registration Number
- NCT00337454
- Locations
- 🇯🇵
Local Institution, Tokyo, Japan
Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2010-07-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 61
- Registration Number
- NCT00337467
- Locations
- 🇪🇸
Local Institution, Malaga, Spain
© Copyright 2024. All Rights Reserved by MedPath